Pharmaceutical giant AstraZeneca has reportedly started looking for candidates to replace CEO Pascal Soriot, following pressure from shareholders. This comes after the UK-based firm on Friday said its drug Imfinzi did not meet the main goal of improving survival rates for lung cancer patients, thereby putting pressure on its shares. The 59-year-old has headed the company for six years.